The more recent research resulting in the lung cancer test came out of a European Union grant involving the university and Oncimmune.

The EarlyCDT-Lung test's target population is high-risk individuals, from long-term and ex-smokers over the age of 40 to people exposed to radon, asbestos, or extensive second-hand smoke.

Oncimmune says EarlyCDT-Lung will be available in the U.S. via primary care physicians and pulmonologists, and the company will bill private insurance companies as well as government-run Medicare Part B carriers on behalf of the patient.

"I am very pleased that the initial exciting research data that we produced in the laboratories at the University of Nottingham a number of years ago have been translated by Oncimmune to the first of many tests that will help us identify cancer early," Robertson said. "It has been a long and at times very hard road in creating a robust commercial test."

上一页  [1] [2]